AS1411 alters subcellular distribution of PRMT5 in a time-dependent, dose-dependent, and nucleolin-dependent manner. AS1411 alters subcellular distribution of PRMT5 in a time-dependent, dose-dependent, and nucleolin-dependent manner. Nuclear and cytoplasmic extracts were prepared from DU145 cells that had been treated with either AS1411 (A) or control oligonucleotide (C). Extracts were analyzed by Western blotting for PRMT5, then for β-actin (a control for equal loading). A, cells were incubated with 10 μmol/L of AS1411 for the times indicated. B, cells were incubated for 24 h with oligonucleotide at the concentrations indicated. C, cells were transfected with either nucleolin siRNA or control siRNA for 48 h before treatment with 10 μmol/L oligonucleotide and then analyzed by Western blotting after a further 24 h. All panels show representative Western blots and quantification of the results using densitometry. The intensity of the PRMT5 band in each sample was normalized to the corresponding β-actin band and expressed relative to the untreated sample. Columns, mean of three independent experiments; bars, SE. Yun Teng et al. Cancer Res 2007;67:10491-10500 ©2007 by American Association for Cancer Research